Mobile Menu

  • AboutUs_Normal-24 The EyeCRO Approach
    • About Us
    • Careers
    • Location
    • Partners
  • MiDrops MiDROPS™
  • InVivo Models
    • Allergic Conjunctivitis
    • Blue Light Damage
    • Corneal Sensitivity
    • Corneal Wound Healing
    • Diabetic Keratopathy
    • DL-AAA Retinal Leakage
    • Dry Eye Disease
    • Endotoxin induced Uveitis
    • Experimental Autoimmune Uveitis
    • Geographic Atrophy
    • Inherited Retinal Degenerations
    • Ischemia Reperfusion Injury
    • Laser-induced Choroidal Neovascularization
    • Mitochondrial Neuropathy
    • MNU-induced Retinal Degeneration
    • Optic Nerve Crush
    • Oxygen Induced Retinopathy
    • Retinal Detachment
    • Retinal Vein Occlusion
    • STZ-induced Diabetic Retinopathy
    • VEGF-induced permeability
  • InVitro Capabilities
    • A2E Quantification
    • Bioanalytical Detection
    • Biochemistry
    • Histology
    • Ophthalmic Imaging and Physiology
  • News News
  • ContactUs Contact Us
  • Menu
  • Skip to primary navigation
  • Skip to main content

EyeCRO

  • AboutUs_Normal-24 The EyeCRO Approach
    • About Us
    • Careers
    • Location
    • Partners
  • MiDrops MiDROPS™
  • InVivo Models
    • Allergic Conjunctivitis
    • Blue Light Damage
    • Corneal Sensitivity
    • Corneal Wound Healing
    • Diabetic Keratopathy
    • DL-AAA Retinal Leakage
    • Dry Eye Disease
    • Endotoxin induced Uveitis
    • Experimental Autoimmune Uveitis
    • Geographic Atrophy
    • Inherited Retinal Degenerations
    • Ischemia Reperfusion Injury
    • Laser-induced Choroidal Neovascularization
    • Mitochondrial Neuropathy
    • MNU-induced Retinal Degeneration
    • Optic Nerve Crush
    • Oxygen Induced Retinopathy
    • Retinal Detachment
    • Retinal Vein Occlusion
    • STZ-induced Diabetic Retinopathy
    • VEGF-induced permeability
  • InVitro Capabilities
    • A2E Quantification
    • Bioanalytical Detection
    • Biochemistry
    • Histology
    • Ophthalmic Imaging and Physiology
  • News News
  • ContactUs Contact Us

Preclinical Ophthalmic Contract Research

EyeCRO specializes in preclinical ophthalmic studies to examine the efficacy of novel test agents and therapeutic modalities.  Our models are well established and optimized to facilitate generation of reproducible datasets with meaningful endpoints.
With over two decades of experience in vision research, our expert scientists can help you select the right model and experimental design to achieve your research and development goals.  We also offer Toxicology/PK studies, and eyedrop formulations in MiDROPS™.

  • 5G2A9861
  • cnv
  • goggles
  • slide
  • okt
  • ideas
  • erg
  • injection
  • 5G2A0010
  • 5G2A9931
  • micron
  • Companies Serviced by EyeCRO 2022
  • 5G2A9841
  • ded

The Global Leader in Preclinical Ophthalmic Research

Microemulsion Drug Ocular Penetration System MiDROPS™

MiDROPS™ was developed to allow for eyedrop formulation of small molecules that are lipophilic.  This technology represents a fundamentally new approach for ophthalmic drug delivery using microemulsions which are thermodynamically stable.  These self-assembling vehicles can formulate high concentrations of drugs and deliver them in abundant quantities to both the anterior segment and posterior segment.  Our broad patents are issued in the US and Worldwide and protect millions of different formulations covered in our library.

midrops vials

Click here to learn more about this innovative platform technology

Models

Allergic Conjunctivitis

Blue Light Damage

Corneal Sensitivity

Corneal Wound Healing

Diabetic Keratopathy

DL-AAA Retinal Leakage

Dry Eye Disease

Endotoxin induced Uveitis

Experimental Autoimmune Uveitis

Geographic Atrophy

Inherited Retinal Degenerations

Ischemia Reperfusion Injury

Laser-induced Choroidal Neovascularization

Mitochondrial Neuropathy

MNU-induced Retinal Degeneration

Optic Nerve Crush

Oxygen Induced Retinopathy

Retinal Detachment

Retinal Vein Occlusion

STZ-induced Diabetic Retinopathy

VEGF-induced permeability

Capabilities

A2E Quantification

Bioanalytical Detection

Biochemistry

Histology

Ophthalmic Imaging and Physiology

News & Events

EyeCRO joins Novo Nordisk, Novartis, Sanofi, Merck KGaA Darmstadt Germany, Lundbeck, and Leo Pharma to prioritize animal welfare in scientific research by signing the Marseille Declaration

“Toward enhancing ethical practices in scientific research, EyeCRO has joined several industry-leading companies to sign the “Marseille Declaration”, the first joint pharmaceutical industry declaration on animal housing and use.” Click here to read the full press…

EyeCRO joins Novo Nordisk, Novartis, Sanofi, Merck KGaA Darmstadt Germany, Lundbeck, and Leo Pharma to prioritize animal welfare in scientific research by signing the Marseille DeclarationRead More

EyeCRO scientist contributes to a paper published in Experimental Eye Research

EyeCRO scientist Jarrod Harman contributed to a paper focused on X-linked juvenile retinoschisis published in Experimental Eye Research. This paper expands the mechanistic understanding of XLRS. Read the full paper here https://www.sciencedirect.com/science/article/pii/S0014483523002129?dgcid=coauthor

EyeCRO scientist contributes to a paper published in Experimental Eye ResearchRead More

EyeCRO scientists contribute to paper published in Biology

Therapeutic Effects of Fenofibrate Nano-Emulsion Eye Drops on Retinal Vascular Leakage and Neovascularization Click here to read more

EyeCRO scientists contribute to paper published in BiologyRead More

EyeCRO scientists contribute to study published in Experimental Eye Research

Intravitreal administration of small molecule read-through agents demonstrate functional activity in a nonsense mutation mouse model. Click here to read more

EyeCRO scientists contribute to study published in Experimental Eye ResearchRead More

InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids

Inmed Pharmaceuticals Inc. (NASD: INM) has secured a worldwide license to formulate any cannabinoid molecule using MiDROPS® for ophthalmic instillation. Click here to read the full press release.

InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic CannabinoidsRead More

EyeCRO scientists contribute to study published in Nature

“Researchers have discovered a technique for directly reprogramming skin cells into light-sensing rod photoreceptors used for vision. The lab-made rods enabled blind mice to detect light after the cells were transplanted into the animals’ eyes. The…

EyeCRO scientists contribute to study published in NatureRead More

View All Posts

EyeCRO on Twitter

eyecro EyeCRO @eyecro ·
September 7, 2023

Nice Laser CNV data! 😉😄

Lentiviral delivered aflibercept OXB-203 for treatment of neovascular AMD: Molecular Therapy - Methods & Clinical Development

Reply on Twitter 1699731093371363606 Retweet on Twitter 1699731093371363606 Like on Twitter 1699731093371363606 Twitter 1699731093371363606
Retweet on Twitter EyeCRO Retweeted
retinatoday Retina Today @retinatoday ·
August 20, 2023

In this article, we highlight some of the latest ongoing phase 2 and 3 gene therapy trials to help #retinaspecialists provide their patients with every available option.

Reply on Twitter 1693327425747177772 Retweet on Twitter 1693327425747177772 9 Like on Twitter 1693327425747177772 24 Twitter 1693327425747177772
Retweet on Twitter EyeCRO Retweeted
sparingvision SparingVision @sparingvision ·
August 16, 2023

Our gene-independent gene therapy product SPVN20 targets retinitis pigmentosa (RP) as the first indication 👀 Let’s take a closer look…

https://sparingvision.com/spvn20_30/

Reply on Twitter 1691761790395240727 Retweet on Twitter 1691761790395240727 4 Like on Twitter 1691761790395240727 7 Twitter 1691761790395240727
Retweet on Twitter EyeCRO Retweeted
arvoinfo ARVO @arvoinfo ·
August 14, 2023

Attention eye and #vision researchers from developing countries! Apply for an @ARVOinfo Foundation Collaborative Research Fellowship for a chance to receive up to $10,000 for a 1-year collaborative research project. Don't miss this amazing opportunity! https://bit.ly/2xFOjG1

Reply on Twitter 1691089818933940225 Retweet on Twitter 1691089818933940225 3 Like on Twitter 1691089818933940225 6 Twitter 1691089818933940225
Load More...

Contact Us

pen and post it

EyeCRO – Headquarters

5301 N. Beverly Drive
Oklahoma City, OK 73105

EyeCRO – Ann Arbor

2725 S. Industrial Hwy, Suite 150
Ann Arbor, MI 48104

info@eyecro.com

Request more information

  • This field is for validation purposes and should be left unchanged.

© 2023 · EyeCRO · All Rights Reserved.